In silico analysis showed that lenalidomide, but not rituximab or fludarabine-chlorambucil regimen, significantly increased LAG-3 expression on leukemic cells, suggesting that LAG-3 blockade may potentiate the anti-tumor effect of the immunomodulatory drug. The gene discussed is LAG3; the disease is neoplasm.